Send to

Choose Destination
Nat Med. 1996 Oct;2(10):1109-15.

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.

Author information

Veterans Affairs Medical Center, Portland, Oregon 97201, USA.

Erratum in

  • Nat Med 1997 Feb;3(2):240.


A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center